Dentsply Sirona
United States · www.dentsplysirona.com · 7 vendors
Resilience scores
- Digital Sovereignty: 86
- Digital Resilience: 8
- Financial Resilience: 5
Technology vendors
- Adobe Inc. — Technology — United States
- Demandware — Technology — United States
- Netlify, Inc. — Technology — United States
- and 4 more
Services catalogue
2 services in catalogue across 2 categories; runs on 7 sub-vendors.
- E4D CAD/CAM solutions
- Sidexis
Insights
Last updated 2026-09-13 · revision 1
7 direct vendors, 160 subvendors
Direct vendors by controlling owner country (sample)
- United States: 6
- Canada: 1
Subvendors by controlling owner country (sample)
- Germany: 2
- Australia: 4
- United Kingdom: 4
Migration Readiness: 7/10
Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.
Dentsply Sirona exhibits a strong foundation for migration readiness, largely due to its strategic adoption of cloud-native technologies for its flagship products. The DS Core platform, being cloud-based and delivered via web browser without requiring local software, signifies a modern, flexible architecture highly conducive to cloud migration and digital transformation. The internal tech stack also highlights the use of other cloud-based SaaS platforms. However, significant challenges and unknowns temper the overall readiness score. Crucially, data residency requirements and the regulatory environment are 'Not specified' or '[]', which are critical factors that can heavily influence migration complexity, cost, and feasibility. The absence of financial data also prevents an assessment of the company's capacity to fund a large-scale migration. Regarding vendor relationships, the data is contradictory ('Total Vendors: 0' vs. 'Total Services: 8' from vendors in 2 countries). Assuming vendors exist, their geographic concentration in only two countries (United States, Canada) for 8 services could introduce vendor lock-in risks and increase migration complexity, particularly if these vendors are deeply integrated into critical systems. The vendor lock-in risk itself is 'Unknown'.
Compliance
12 in-scope frameworks identified; showing 3.
EU Medical Device Regulation — Partially Compliant
Dentsply Sirona sells medical devices (dental implants, imaging systems, intraoral scanners, CAD/CAM systems) across the EU, making EU MDR 2017/745 fully applicable. Risk is rated High because: (1) EU MDR has significantly stricter requirements than the previous MDD, including enhanced clinical evidence requirements, post-market clinical follow-up (PMCF), and Unique Device Identification (UDI); (2) the transition deadlines have created compliance pressure across the industry; (3) Notified Body capacity constraints have caused delays in MDR certification for many manufacturers; (4) non-compliance can result in market withdrawal of products from the EU; (5) Dentsply Sirona's broad EU product portfolio means multiple device classifications and Notified Body interactions are required; (6) the EU MDR's cybersecurity requirements (MDCG 2019-16) apply to DS Core and connected devices. Status is 'Partially Compliant' as the company is an established EU market participant with CE-marked products, but the ongoing MDR transition creates compliance gaps.
Evidence: https://www.dentsplysirona.com/en-us.html, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745, https://www.dentsplysirona.com/en-us/legal/privacy-policy.html
CPRA — Partially Compliant
Dentsply Sirona explicitly addresses CCPA/CPRA compliance in Section 17C of their Privacy Policy with a detailed California-specific disclosure. Risk is rated Medium because: (1) the company acknowledges 'selling' and 'sharing' personal information (identifiers, commercial information, location data, internet activity) with advertising networks and analytics providers, which triggers CCPA opt-out obligations; (2) California AG and CPPA enforcement has been active; (3) the company's scale of US operations (thousands of dental practice customers, consumer-facing website) creates significant CCPA exposure; (4) however, the company has implemented opt-out mechanisms (GPC signal response, 'Do Not Sell or Share' link, webform) which reduces enforcement risk. Status is 'Partially Compliant' as opt-out mechanisms are in place but the ongoing 'sale/sharing' of data for advertising purposes represents a continuing compliance obligation.
Evidence: https://www.dentsplysirona.com/en-us/legal/privacy-policy.html, https://www.dentsplysirona.com/en-us/legal/privacy-policy/consumer-health-data-privacy-policy.html, https://dentsplysirona-privacy.my.onetrust.com/webform/9bbfac2d-3e44-47be-903a-e6719d7bb393/b21f9b93-4e92-40e9-93c7-46351c4273ce
ISO 27001 (source) — Assessment Required
ISO 27001 certification is highly relevant for Dentsply Sirona given their operation of cloud platforms (DS Core), digital health devices (intraoral scanners, imaging systems), and processing of sensitive dental/health data across 150+ countries. Risk is rated Medium because: (1) ISO 27001 is not legally mandated but is increasingly required by enterprise customers, healthcare organizations, and EU regulatory frameworks (NIS2 references ISO 27001 as a recognized standard); (2) without certification, the company may face procurement barriers with large hospital networks and dental chains; (3) the dental technology sector's increasing digitization raises cybersecurity risk; (4) Dentsply Sirona's scale and global operations make information security management critical. No public ISO 27001 certificate has been identified, though the Privacy & Security Trust Center suggests security controls exist.
Evidence: https://coresupport.dentsplysirona.com/doc/cm-trust-center-en-US/-, https://www.dentsplysirona.com/en-us/legal/privacy-policy.html
Financials
Three-year financials
- 2025: revenue USD 3.68B, EBIT USD -422M, equity USD 1.34B
- 2024: revenue USD 3.79B, EBIT USD -879M, equity USD 1.94B
- 2023: revenue USD 3.96B, EBIT USD -85.0M, equity USD 3.29B
Financial Resilience Score: 5/10
Dentsply Sirona demonstrates moderate financial resilience underpinned by its global scale, diversified dental portfolio, and strong brand equity in CEREC, Astra Tech, Atlantis, and SureSmile. The company operates in 150+ countries, invests approximately 4% of revenue in R&D, and generates positive underlying operating cash flow that supports dividends and buybacks even during periods of GAAP losses. Its broad product mix across consumables, equipment, implants, and aligners provides cyclical and geographic diversification. However, resilience has been materially weakened by recurring goodwill and intangible impairments (~$1.2B in 2022 and an additional ~$0.6-0.7B in 2024), signaling that prior M&A returns have disappointed. Revenue declined sharply (~16%) in 2024 due to CAD/CAM weakness, FX headwinds, and softer capital equipment demand. Equity has eroded by ~41% over three years from buybacks combined with impairment-driven losses, constraining balance sheet flexibility. Net-debt/adjusted-EBITDA has trended upward. Governance issues including multiple CEO changes and a resolved SEC investigation related to distributor incentive arrangements add to risk. Organic growth has consistently lagged peers like Align Technology, Envista, and Straumann. The company has launched a Transformation Program targeting ~$200M in cost savings by 2026, but execution risk remains elevated.
Key strengths: Global footprint across 150+ countries provides diversification, Strong brand portfolio (CEREC, Astra Tech, Atlantis, SureSmile), R&D intensity of ~4% of revenue with 650+ scientists/engineers, Positive underlying operating cash flow despite GAAP losses, Broad end-to-end dental portfolio across consumables, equipment, implants, and aligners, Large installed base and entrenched dealer relationships
Risk factors: Recurring goodwill impairments (~$1.2B in 2022, ~$0.6-0.7B in 2024), Sharp ~16% revenue decline in 2024, Equity erosion of ~41% over three years, Demand cyclicality in capital equipment (CAD/CAM, imaging), Multiple CEO changes and resolved SEC investigation on distributor incentives, FX exposure with 60%+ of revenue outside the U.S., Intensifying competition from Align (Invisalign), Straumann, Envista/Nobel Biocare, Rising net-debt/adjusted-EBITDA leverage, Organic growth consistently lagging peers
Revenue by geography
- Europe: 41%
- United States: 34%
- Rest of World (Asia-Pacific, Latin America, CIS, Middle East): 25%
Revenue by product/service
- Essential Dental Solutions (Consumables): 36%
- Orthodontic & Implant Solutions: 29%
- Connected Technology Solutions (CAD/CAM, Imaging, Equipment): 27%
- Wellspect HealthCare: 8%
Workforce by country
- Total Worldwide: 15000
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.